Vaxart, Inc. (VXRT)
NASDAQ: VXRT · IEX Real-Time Price · USD
0.701
-0.014 (-1.97%)
At close: May 1, 2024, 4:00 PM
0.702
+0.001 (0.20%)
After-hours: May 1, 2024, 7:39 PM EDT
Vaxart Revenue
In the year 2023, Vaxart had annual revenue of $7.38M with 6,796.26% growth. Revenue in the quarter ending December 31, 2023 was $3.25M with 14,650.00% year-over-year growth.
Revenue (ttm)
$7.38M
Revenue Growth
+6,796.26%
P/S Ratio
16.79
Revenue / Employee
$67,697
Employees
109
Market Cap
123.89M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
Dec 31, 2019 | 9.86M | 5.70M | 137.12% |
Dec 31, 2018 | 4.16M | -1.68M | -28.77% |
Dec 31, 2017 | 5.84M | -3.46M | -37.22% |
Jun 30, 2016 | 9.30M | -15.30M | -62.20% |
Jun 30, 2015 | 24.60M | -44.10M | -64.19% |
Jun 30, 2014 | 68.70M | 35.10M | 104.46% |
Jun 30, 2013 | 33.60M | 13.20M | 64.71% |
Jun 30, 2012 | 20.40M | 7.90M | 63.20% |
Jun 25, 2011 | 12.50M | -22.51M | -64.29% |
Dec 25, 2010 | 35.01M | 24.52M | 233.73% |
Dec 26, 2009 | 10.49M | - | - |
Dec 27, 2008 | 0 | - | - |
Dec 29, 2007 | 0 | - | - |
Dec 30, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 25, 2004 | 142.18M | -34.39M | -19.48% |
Dec 27, 2003 | 176.57M | -19.40M | -9.90% |
Dec 28, 2002 | 195.97M | -38.86M | -16.55% |
Dec 29, 2001 | 234.83M | 6.05M | 2.64% |
Dec 30, 2000 | 228.78M | -4.82M | -2.06% |
Dec 31, 1999 | 233.60M | -9.48M | -3.90% |
Dec 31, 1998 | 243.09M | 14.34M | 6.27% |
Dec 31, 1997 | 228.74M | -11.17M | -4.65% |
Dec 31, 1996 | 239.91M | 43.98M | 22.45% |
Dec 31, 1995 | 195.93M | 31.50M | 19.16% |
Dec 31, 1994 | 164.43M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Karyopharm Therapeutics | 146.03M |
Xtant Medical Holdings | 91.30M |
Seer, Inc. | 16.66M |
Molecular Partners AG | 8.38M |
Omega Therapeutics | 3.09M |
Delcath Systems | 2.07M |
VistaGen Therapeutics | 1.04M |
VXRT News
- 1 day ago - Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers - GlobeNewsWire
- 5 weeks ago - Vaxart to Present at World Vaccine Congress Washington 2024 on April 3 - GlobeNewsWire
- 6 weeks ago - Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Vaxart Provides Business Update and Reports Full Year 2023 Financial Results - GlobeNewsWire
- 7 weeks ago - Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14 - GlobeNewsWire
- 2 months ago - Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director - GlobeNewsWire
- 3 months ago - Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge - GlobeNewsWire
- 3 months ago - Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - GlobeNewsWire